Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the ...

Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

DALLAS, Nov. 13, 2024 /PRNewswire/ -- Kimberly-Clark Corporation (NYSE: KMB ) today announced that Joseph Romanelli, president of Human health International for Merck & Co., Inc., Rahway, NJ, USA, ...

Visit www.neptune-software.com. Merck , known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, ...